These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 9527715)

  • 21. Anticholinesterases in Alzheimer's disease: a modest effect on moderately severe disease.
    Prescrire Int; 2003 Dec; 12(68):230-1. PubMed ID: 14986699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
    Cortes F; Portet F; Touchon J; Vellas B
    J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholinergic therapies for Alzheimer's disease. Palliative or disease altering?
    Davis RE; Doyle PD; Carroll RT; Emmerling MR; Jaen J
    Arzneimittelforschung; 1995 Mar; 45(3A):425-31. PubMed ID: 7763338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [[Donepezil : a new option in the treatment of Alzheimer's disease] ONEPA].
    Azanza JR; Sádaba B; Quetglas EG; Escolar M
    Rev Med Univ Navarra; 1998; 42(2):109-18. PubMed ID: 10420948
    [No Abstract]   [Full Text] [Related]  

  • 25. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
    Shao D; Zou C; Luo C; Tang X; Li Y
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4639-42. PubMed ID: 15324879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Balance sheet of tolerance-efficacy on the use of tacrine in 100 cases of Alzheimer's disease].
    Estadieu MC; Machou C; Berthezène P; Pastor MJ; Angelini B; Bohor M; Bongrand MC; Timon-David P; Gastaut JL; Allain H; Michel BF
    Therapie; 1998; 53(1):67-76. PubMed ID: 9773102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tacrine. Alzheimer's disease and the cholinergic theory. A critical review and results of a new therapy.
    Boller F; Orgogozo JM
    Neurologia; 1995 May; 10(5):194-9. PubMed ID: 7619536
    [No Abstract]   [Full Text] [Related]  

  • 29. [The effect of amiridine and tacrine on reversible capture of neuromediators in experimental memory disorders].
    Burov IuV; Baĭmanov TD; Robakidze TN
    Biull Eksp Biol Med; 1995 May; 119(5):512-4. PubMed ID: 7579247
    [No Abstract]   [Full Text] [Related]  

  • 30. Tacrine: a second look. An outdated drug to be discarded.
    Prescrire Int; 1999 Feb; 8(39):16-8. PubMed ID: 10557569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reports from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). The efficacy of Tacrine and the measurement of outcomes of Alzheimer's disease.
    Int J Technol Assess Health Care; 1998; 14(2):398-9. PubMed ID: 9678977
    [No Abstract]   [Full Text] [Related]  

  • 32. [Use of cholinesterase inhibitors in Alzheimer disease].
    Sampalmieri M; Troiani MP; Servi M
    Clin Ter; 1993 Dec; 143(6):549-52. PubMed ID: 8306579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerance to tacrine, arterial hypotension and leuko-araiosis in Alzheimer's disease.
    Lebert F; Mouly C; Pasquier F
    Age Ageing; 1998 Sep; 27(5):654. PubMed ID: 12675108
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical study of patients with Alzheimer's disease under treatment with tacrine].
    García-López MT; Guardado-Santervás P
    Rev Neurol; 2001 Feb 16-28; 32(4):394-7. PubMed ID: 11398762
    [No Abstract]   [Full Text] [Related]  

  • 35. [Should Alzheimer disease be treated with tacrine? Review of the literature].
    Arsland D; Laake K
    Tidsskr Nor Laegeforen; 1996 Sep; 116(23):2791-4. PubMed ID: 8928167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on cholinergic enhancement therapy for Alzheimer disease.
    Read SL
    Bull Clin Neurosci; 1987; 52():34-7. PubMed ID: 3334548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial.
    Brassen S; Adler G
    Pharmacopsychiatry; 2003 Nov; 36(6):304-8. PubMed ID: 14663655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Modifications of Anti-dementia Agents Focusing on Tacrine and/or Donepezil Analogs.
    Mohamed LW; Mohamed KO; Sayed HS; Mahmoud Z
    Med Chem; 2023; 19(4):311-324. PubMed ID: 36043761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacoepidemiology of tacrine in Alzheimer's disease.
    Begaud B; Haramburu F; Miremont G
    Methods Find Exp Clin Pharmacol; 1996; 18 Suppl B():77-8. PubMed ID: 8899701
    [No Abstract]   [Full Text] [Related]  

  • 40. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action.
    Poirier J
    Int J Clin Pract Suppl; 2002 Jun; (127):6-19. PubMed ID: 12139368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.